{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.43","pValueComment":"Competing risks analysis for time to GVHD for subjects with allogeneic HST. The sample size was very small (n=7 in the granulocyte group, and n=8 in the control group).","paramType":"Log Rank P-Value","paramValue":"0.43","statisticalMethod":"Competing Risks","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.67"},{"groupId":"OG001","value":"0.40"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"description":"Time to GVHD incidence between the two treatment groups was compared using Gray's model that takes into account death as a competing risk.","groups":[{"description":"Received antimicrobial therapy alone.","id":"OG000","title":"Control Arm"},{"description":"Received G-CSF/dexamethasone-mobilized granulocyte transfusions in addition to antimicrobial therapy.","id":"OG001","title":"Granulocyte Arm"}],"paramType":"NUMBER","populationDescription":"Subjects who had allogeneic stem cell transplantation","reportingStatus":"POSTED","timeFrame":"Measured at Day 42","title":"Graft Versus Host Disease Among Recipients of Allogeneic Stem Cell Transplantation","type":"SECONDARY","unitOfMeasure":"proportion of subjects, GVHD incidnence"}